Bavarian Nordic to Supply 13 Million Doses of MPox Vaccine by 2025
Copenhagen: Bavarian Nordic, a Danish biotech company, announced on Thursday that it could supply 13 million doses of its MPox vaccine by the end of 2025, up from a previous forecast of 10 million doses. The company is exploring options to significantly expand its capacity.
Bavarian Nordic’s head of investor relations, Rolf Sass Sorensen, said, "It depends first and foremost on demand. If the demand is there and the other conditions are in place, we have the opportunity to increase by another 50 million doses."
The World Health Organization declared MPox a global health emergency last month, but efforts to curb the spread of the disease have been hampered by a lack of vaccines. Sorensen said supply also hinges on ongoing discussions about collaborations with partners in Africa and elsewhere regarding the transfer of manufacturing, alongside the adoption of other methods and technologies with a higher yield.
Bavarian said certain existing orders for MPox vaccines based on contracts with the U.S. government would be pushed back to 2025 from 2024 in order to meet other market needs.
The Democratic Republic of Congo, the epicenter of the latest MPox outbreak, received its first batch of MPox vaccines last week.
Reporting by Louise Breusch Rasmussen and Stine Jacobsen, editing by Essi Lehto, Terje Solsvik and Christina Fincher.
Published on Sep 13, 2024 at 07:10 AM IST
Category: Most Read Placement
Comment Section
Subscription in Article
Join the community of 2M+ industry professionals
Subscribe to our newsletter to get latest insights & analysis.
Download ETHealthworld App
Get Realtime updates
Save your favourite articles
Reference : https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/bavarian-nordic-sees-potential-to-ramp-up-mpox-vaccine-capacity/113306994
